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Abstract
Background: In order to improve malaria burden estimates in low transmission settings, more sensitive tools and
efficient sampling strategies are required. This study evaluated the use of serological measures from repeated
health facility-based cross-sectional surveys to investigate Plasmodium falciparum and Plasmodium vivax
transmission dynamics in an area nearing elimination in Indonesia.
Methods: Quarterly surveys were conducted in eight public health facilities in Kulon Progo District, Indonesia, from
May 2017 to April 2018. Demographic data were collected from all clinic patients and their companions, with
household coordinates collected using participatory mapping methods. In addition to standard microscopy tests,
bead-based serological assays were performed on finger-prick bloodspot samples from 9453 people.
Seroconversion rates (SCR, i.e. the proportion of people in the population who are expected to seroconvert per
year) were estimated by fitting a simple reversible catalytic model to seroprevalence data. Mixed effects logistic
regression was used to examine factors associated with malaria exposure, and spatial analysis was performed to
identify areas with clustering of high antibody responses.
Results: Parasite prevalence by microscopy was extremely low (0.06% (95% confidence interval 0.03–0.14, n = 6)
and 0 for P. vivax and P. falciparum, respectively). However, spatial analysis of P. vivax antibody responses identified
high-risk areas that were subsequently the site of a P. vivax outbreak in August 2017 (62 cases detected through
passive and reactive detection systems). These areas overlapped with P. falciparum high-risk areas and were
detected in each survey. General low transmission was confirmed by the SCR estimated from a pool of the four
surveys in people aged 15 years old and under (0.020 (95% confidence interval 0.017–0.024) and 0.005 (95%
confidence interval 0.003–0.008) for P. vivax and P. falciparum, respectively). The SCR estimates in those over 15
years old were 0.066 (95% confidence interval 0.041–0.105) and 0.032 (95% confidence interval 0.015–0.069) for P.
vivax and P. falciparum, respectively.
Conclusions: These findings demonstrate the potential use of health facility-based serological surveillance to better
identify and target areas still receptive to malaria in an elimination setting. Further implementation research is
needed to enable integration of these methods with existing surveillance systems.
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Background
Transforming malaria surveillance into a core intervention
is one of the three pillars of the WHO global technical strat-
egy for malaria elimination [1]. As transmission declines,
malaria risk becomes more heterogeneous and is often clus-
tered in specific localities or populations [2, 3]. Identifying
areas of ongoing infection or areas at risk of outbreaks is
important to ensure that control strategies can be deployed
in the most efficient manner [4–6]. In many Southeast Asian
settings, surveillance becomes more challenging with the
presence of multi-species infections combined with the
difficulty of identifying where, and in which populations,
residual transmission might be occurring [7, 8].
In many countries, surveillance has focused on passive
case detection performed via health facilities [9, 10].
However, innovative additional strategies are needed in
countries nearing elimination as malaria cases become
increasingly rare and disproportionately affect high-risk
populations, who may not utilise public health facilities
[10]. Studies suggest that passive surveillance will miss a
large proportion of asymptomatic and sub-microscopic
infections present in the community [8, 11, 12] and may
also not optimally capture imported infections occurring
in temporary visitors who may be unable or unlikely to
visit a health facility. Effectively targeting both of these
groups is likely to hasten progress toward elimination.
Resurgence of malaria is often associated with imported
infections and/or P. vivax relapsing infections in areas that
remain highly receptive to malaria [13–16]. Studies have
demonstrated the usefulness of spatially referenced ento-
mological data to characterise the heterogeneity of malaria
receptivity in areas approaching elimination to prevent
outbreaks in the future [17–19]. However, entomological
surveillance can often be logistically challenging in low
transmission areas due to the difficulty of catching mean-
ingful numbers of mosquitoes. An alternative approach is
to identify areas where the population show evidence of
current or previously high malaria exposure. This can be
done using serological markers of infection and identifying
populations with higher than average anti-malaria anti-
bodies [20–23]. Serological measures are a sensitive tool to
estimate current and previous transmission intensity in a
population and their use has been particularly well
validated in low transmission areas where the sensitivity of
parasitological tools is inadequate [24–27]. However, these
studies used community-based cross-sectional surveys that
often require large resources to visit households for col-
lecting samples and household global positioning system
coordinates to map the transmission risk. In order to fur-
ther reduce logistical constraints, convenience sampling
approaches targeting health facility attendees can be used
to estimate and map risks in a population when household
surveys are not feasible [28] and has been shown to be a
good proxy for malaria transmission in the community
[29]. Moreover, the simple addition of a geolocation ap-
proach to remotely record the residence of health facility
attendees in the survey [30] allows for rapid assessment of
the micro-epidemiology of malaria cases in the community
and could help to identify geographical foci of exposure.
Indonesia is one of countries facing challenges in elimin-
ating both Plasmodium falciparum and Plasmodium vivax
infections. Previous studies in Indonesia suggest that the
current diagnostic sensitivity (microscopy and rapid diag-
nostic test (RDT)) and timeliness of transmission measure-
ment are not sufficient to describe and predict decreasing
numbers of cases and potential outbreaks in low transmis-
sion areas striving for elimination [31–33]. The risk of out-
breaks is high where there are larger numbers of migrants
or travellers [31, 34–36] and/or where residents with
asymptomatic infections are not actively seeking treatment
for malaria [37–45]. Therefore, surveillance systems need
to be improved to better locate and target infections and
further reduce transmission [32, 46]. This study evaluated
the use of serology, geolocation tools, and repeated health
facility-based surveys for capturing malaria transmission
dynamics in conjunction with existing surveillance system
in an area conducting elimination in Indonesia.
Methods
Study setting
Indonesia has the second highest burden of malaria in
the Southeast Asia region, with an estimated 16 million
people (~ 6% of the population) living in high-risk areas
[47]. All species of Plasmodium have been reported in
Indonesia with the majority of infections caused by P.
falciparum and P. vivax [35, 48–51]. Malaria transmis-
sion is highly heterogenous [52, 53], with large areas
being transmission free, leading to a governmental target
of achieving malaria elimination across the country by
2030 [46]. This study was conducted in Kulon Progo
District, Yogyakarta Province, Indonesia, located on the
south coast of Java Island. Kulon Progo is one of the few
remaining foci of malaria transmission on Java Island,
Indonesia (Fig. 1). The study site consists of 12 sub-
districts (586 km2 in total) with a population of approxi-
mately 430,500 people in 2016. Each district has at least
one public health facility (21 in total). Malaria transmis-
sion is concentrated in the forested hillside area that
border with other endemic areas of Central Java Prov-
ince [54]. Transmission occurs during the wet season
between August and December, with very low or zero
cases during the other months. Based on routine passive
data recorded in local health facilities, there was a sig-
nificant decline in malaria annual parasite incidence
from 0.48 per 1000 population in 2012 to 0.22 per 1000
population in 2016. Eight health facilities in 5 sub-
districts where P. falciparum and/or P. vivax transmis-
sion was ongoing were chosen as study sites. Anopheles
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maculatus and Anopheles balabacencis are the main
malaria vectors in Kulon Progo [55].
Survey design and data collection
The study population included all attendees of the eight
selected public health facilities. Surveys were conducted
quarterly during the period of May 2017 to April 2018.
Each survey continued until the minimum sample size was
met. The sample size calculation was performed using
methods specific for estimating antibody seroconversion
rates (SCR, i.e. the proportion of people in the population
who are expected to seroconvert per year) [56]. The SCR to
either P. falciparum apical membrane antigen 1 (PfAMA1)
or merozoite surface protein 1 (PfMSP-1-19) in Kulon
Fig. 1 Maps showing the location of Yogyakarta Province in Indonesia (a), location of Kulon Progo District in Yogyakarta Province (b), and the
location of eight studied health facilities in Kulon Progo District (c). Tree cover data, derived from classified Landsat imagery at 30-m resolution,
were obtained from Hansen et al. [57]
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Progo was expected to be lower than the SCR reported in
the neighbouring pre-elimination setting, Purworejo Dis-
trict, Indonesia (SCR 0.019 (95% CI 0.015–0.022)). There-
fore, a minimum sample size of 248 individuals per facility
was set to ensure an antibody SCR of 0.0036 could be esti-
mated with a precision level of +/− 0.0018.
Finger-prick blood samples were collected as dried
bloodspots together with thick and thin blood smears
from all consenting participants attending the facilities.
Patients who were very ill and required urgent care, and
children < 6months of age were excluded. Data on age,
gender, axillary temperature, patient (versus accompany-
ing person) status, permanent residence, travel behaviour,
occupation, bed net use and current symptoms or reasons
for attending the clinic were collected. Fever status was
defined as having axillary temperature > 37.5 °C and/or re-
ported having fever in the previous 24 h of sample collec-
tion. Participants were asked to geolocate their household
using high-resolution digital offline maps via the open
source GeoODK. The validation of this mapping approach
was performed at the beginning of our first survey and has
been reported in Fornace et al. [30]. All data were col-
lected via interview using open data kit (https://opendata-
kit.org/) on tablets (Samsung Galaxy Tab 3 SM-T210).
Demographic data on reported cases, surveillance (passive
and reactive case findings) and control programme activ-
ities were collected from the District Health Office of
Kulon Progo in between every serological survey. Data on
the age distribution of the population in the study area
was obtained from the 2016 census published by the
Central Agency on Statistics of Kulon Progo. Tree cover
data, derived from classified Landsat imagery at 30m reso-
lution, were obtained from Hansen et al. [57].
Laboratory methods
Thick and thin blood smears were read by trained health
facility lab technicians at each facility. Bloodspot samples
were tested against a panel of P. falciparum and P. vivax
antigens including apical membrane antigen 1 (PfAMA1;
PvAMA-1), merozoite surface protein 1 (PfMSP-1-19;
PvMSP-1-19), erythrocyte binding protein (PvEBP), re-
ticulocyte binding protein 1a [amino acids 160–1170]
(PvRBP1a) and reticulocyte binding protein 2b [amino
acids 161–1454] (PvRBP2b) using a bead-based assay as
described by Wu et al. [58] and read using Luminex
MAGPIX© (Luminex Corp, Austin, TX). For serological
data analysis, infants under 1 year of age were excluded
from each dataset to remove any influence of maternally
derived antibodies [59]. Antibody responses measured as
median fluorescence intensity (MFI) values were normal-
ised against the MFI values of the positive control run
on each plate. For each plate, the percentage of plate-to-
reference standard MFI difference was calculated and
used to adjust the median MFI values.
Statistical analysis
All statistical analyses were conducted in Stata IC 15
(Stata Corp, College Station, TX, USA). A cut-off for
seropositivity was determined based on finite mixture
models according to the mean of log MFI values plus
three standard deviation of the seronegative population.
Separate cut-off values were generated for each antigen
[60]. Individuals were categorised as seropositive for
each species if their antibody responses were above the
cut-off for either of the two or five antigens for P. falcip-
arum and P. vivax, respectively. SCR were estimated by
fitting a reverse catalytic model to seroprevalence data
for each species [59]. Models allowing two forces of in-
fection in SCR were fitted if deemed a better fit, using
likelihood ratio methods. Mixed effects logistic regres-
sion models were performed to examine risk factors as-
sociated with being seropositive to P. vivax. Variables
with evidence of an association (p < 0.05) in bivariate
analysis were included in a multivariable model. Health
facility was treated as a random effect variable in both
bivariate and multivariable models.
Spatial analysis
The ‘Normal model’ in the spatial software SaTScan
(v.9.4.2) was used to detect clusters of individuals with
higher than average age-adjusted antibody responses to
each antigen per survey. In order to obtain age-adjusted
values, the MFI data were log10 transformed and the re-
siduals from linear regression were used to determine
whether antibody responses were higher or lower than
expected for any given age assuming a homogeneous
distribution of risk across age. Firstly, residuals were
categorised into four categories, i.e. below 25th percent-
ile, 25th–75th percentile, 75th–90th percentile and
above 90th percentile for each antigen. Individuals were
then assigned score 4 (highest) if they had residual
values above the 90th percentile, 3 (higher than average)
for 75–90th percentile, 2 (average) for 25–75th percent-
ile and 1 (low) for residual below the 25th percentile to
any of the two or five antigens for P. falciparum or P.
vivax antigen, respectively. The residual scores were
then used to calculate non-overlapping, statistically
significant (p < 0.05) clusters of higher than average age-
adjusted antibody responses with a maximum radius of
3 km, minimum 2 observations detected in a cluster
using the Purely Spatial scan. The analysis was run
separately for each survey to ascertain spatial pattern at
each survey time point. Clusters identified from SatScan
were then plotted in QGIS software (v.3.6.3) to identify
the potentially receptive areas. Spatial autocorrelation
for each survey time point was assessed using Moran’s I
in ArcGIS (v.10.5) using the age-adjusted antibody resid-
uals from the regression model.
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Results
Study enrolment and population demographics
A total of 9453 individuals were sampled during four re-
peated cross-sectional surveys performed in eight health
facilities in Kulon Progo District, Yogyakarta Province,
Indonesia, during the period of May 2017 to April 2018
(Table 1). Blood smears and dried bloodspot samples were
collected from > 98% of attendees and their companions.
Participation rates were above 90% for all surveys, ranging
from 82 to 100% across facilities. Study participants were
mostly female (65%), the median age was 42 years old
(IQR 27–55), and the majority attended the facilities as
patients (78.6%). Children were underrepresented in the
sample, in comparison to the general population. Ap-
proximately 30% of the study population were forest
workers involved in coconut/palm tapping, fruit farming,
logging and other related jobs. A total of 42% of the study
population reported having at least one bed net in their
house, resulting in overall usage of 27% in the study popu-
lation. Only 16% of the population reported recent travel,
with the highest proportion of travel recorded during
quarters 1 and 2 (May to October 2017). Approximately
5% of the study population were febrile or reported having
fever in the previous 24 h.
Data captured by routine passive surveillance during the
study period
The routine passive and reactive case detection in the
study area detected 72 P. vivax and 8 P. falciparum
microscopy-positive infections out of 15,067 slides read
in 2017, with the majority of infections found in males
(70.2%) and adults over 15 years old (89.0%). All P. fal-
ciparum infections were classified as imported. The ma-
jority of the P. vivax infections (86.1%, n = 62) were
found in Kokap 1 health facility catchment area in quar-
ter 2 (74%, n = 46). Of all of the infections detected, 39%
(n = 24) were detected passively at the health facility,
with the rest being detected via door to door active case
detection performed by the village malaria workers (i.e.
screening of suspected cases based on clinical signs).
The P. vivax cases found through active case detection
in Kokap 1 area were classified as a malaria outbreak by
Table 1 Number of samples, participation rates and general characteristics of health facility attendees per survey
Quarter 1 Quarter 2 Quarter 3 Quarter 4 Total
(May–July) (August–October) (November–January) (February–April)
Sample size, n 2363 2370 2379 2341 9453
n per facility
Kokap 1 299 300 286 300 1185
Kokap 2 298 298 297 301 1194
Samigaluh 1 298 300 298 299 1195
Samigaluh 2 300 297 300 280 1177
Kalibawang 296 300 298 263 1157
Girimulyo 1 285 299 300 299 1183
Girimulyo 2 300 276 300 299 1175
Pengasih 2 287 300 300 300 1187
Participation rates
Mean % 95 96 91 96 94
Range* 91–99 90–99 82–99 90–100 91–96
Female, n (%) 1578 (66.8) 1527 (64.4) 1530 (64.3) 1502 (64.2) 6137 (64.9)
Age, median (IQR) 40 (25–54) 41 (27–54) 42 (27–55) 43 (30–57) 42 (27–55)
Patients, n (%) 1803 (76.3) 1939 (81.8) 1878 (78.9) 1812 (77.4) 7432 (78.6)
Occupation, n (%)
Forest workers 655 (27.7) 709 (29.9) 620 (26.1) 800 (34.2) 2784 (29.5)
Non-forest workers 685 (29.0) 647 (27.3) 738 (31.0) 678 (29.0) 2748 (29.1)
Not working 1023 (43.3) 1014 (42.3) 1021 (42.9) 859 (36.8) 3917 (41.5)
Lives in a house with bed net, n (%) 1091 (46.2) 1132 (47.8) 999 (42.0) 777 (33.3) 3999 (42.3)
Slept under the bed net, n (%) 710 (30.1) 685 (28.9) 666 (28.0) 527 (22.5) 2588 (27.4)
Recent travel, n (%) 595 (25.2) 581 (24.6) 211 (8.9) 111 (4.7) 1498 (15.9)
Fever, n (%) 127 (5.4) 116 (5.0) 146 (6.1) 93 (4.0) 484 (5.2)
*Range of health facility-level summaries
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local authorities as there had been no indigenous case
reported in the area since 2016, with only 2 P. vivax re-
lapsed cases reported in July 2017.
Health facility-based serological surveillance
Few microscopy-positive infections were detected; 6/
9356 (0.06%, 95% CI 0.03–0.14) for P. vivax and no P.
falciparum-positive individuals were identified. All infec-
tions were found in Kokap 1 health facility, with 5 infec-
tions detected in quarter 2 and 1 in quarter 4. Of these
infections, 1 was from a companion and 5 were from pa-
tients not suspected of having malaria. Most of the in-
fections were asymptomatic (66.7%) (i.e. afebrile).
Seroprevalence to P. vivax antigens was higher than
seroprevalence to P. falciparum antigens in all surveys
(Table 2). As expected, the seroprevalence increased
with age for both species and varied between health fa-
cilities and over time. The highest overall seroprevalence
was found in quarter 2 (August to October 2017), 46.3%
(95% CI 44.2–48.3) and 23.9% (95% CI 22.2–25.7) for P.
vivax and P. falciparum, respectively, with similar pat-
terns observed according to a proportion of higher than
average age-adjusted antibody responses to multiple an-
tigens (Fig. 2).
Transmission intensity and factor associated with
transmission
Based on the population-level SCR values, and consist-
ent with microscopy and routine reporting data, the
transmission intensity was higher for P. vivax than P.
falciparum. The SCR model estimates (Fig. 3) suggested
that there was evidence for two forces of infection. The
P. vivax SCR was 0.020 person-year (95% CI 0.017–
0.024) and 0.066 person-year (95% CI 0.041–0.105) for
≤ 15 and over 15 years old, respectively. The P. falcip-
arum SCR was 0.005 person-year (95% CI 0.003–0.008)
and 0.032 person-year (95% CI 0.015–0.069) for ≤ 15
and over 15 years old, respectively. At a health facility
level, P. vivax SCR model estimates (Fig. 4) showed evi-
dence for two forces of infection only in two health facil-
ities where active cases were identified. However, a
number of samples were low in the youngest age groups
which may have influenced the fitting and estimates.
Multivariable analysis found gender, occupation, time of
survey and bed net use were significantly associated with
being P. vivax seropositive, after controlling for other
covariates factors (Table 3). The odds of being seroposi-
tive was higher in males (aOR 1.3, 95% CI 1.2–1.5), for-
est goers (aOR 1.2, 95% CI 1.0–1.3), those reporting
sleeping under a bed net (aOR 1.2, 95% CI 1.1–1.3) and
during quarter 2 (aOR 1.5, 95% CI 1.3–1.6).
Heterogeneity of transmission
Moran’s I suggested significant spatial autocorrelation
for both species at each time point. The spatial analysis
of higher than average age-adjusted antibody responses
to multiple P. vivax antigens (Fig. 5) identified the same
village in the Kokap 1 catchment area prior to when the
P. vivax outbreak occurred during the quarter 2 (out-
break started in early August 2017, in between the first
and second survey). The analysis consistently identified
significant clusters of P. vivax exposure in catchment
areas of Kokap 1 and Kokap 2 in each survey. These
catchments were areas where active infections were de-
tected by the existing surveillance in quarters 1, 2 and 3,
with no cases in quarter 4. Significant clusters were also
identified in Samigaluh 2 in quarters 2 and 4, and in Gir-
imulyo 2 in quarter 4. The same areas were also identi-
fied using P. falciparum antigens (Additional file 1:
Figure S1). In addition, the spatial analysis suggests that
the P. vivax clusters identified were also the place where
Table 2 Seroprevalence to P. vivax and P. falciparum at quarterly surveys
Quarter 1
(May–July)
Quarter 2
(August–October)
Quarter 3
(November–January)
Quarter 4
(February–April)
Number
positive
Seroprevalence%
(95% CI)
Number
positive
Seroprevalence
% (95% CI)
Number
positive
Seroprevalence
% (95% CI)
Number
positive
Seroprevalence
% (95% CI)
P. vivax
Age group
1–15 years old 44 12.1 (8.0–17.8) 24 11.2 (7.6–16.2) 26 17.6 (12.2–24.6) 9 10.5 (5.5–18.9)
> 15 years old 1014 41.0 (38.9–43.1) 1000 50.1 (47.9–52.3) 906 41.6 (39.6–43.7) 918 41.8 (39.8–43.9)
All ages 1058 38.8 (36.8–40.8) 1024 46.3 (44.2–48.3) 932 40.1 (38.2–42.1) 927 40.7 (38.7–42.7)
P. falciparum
Age group
1–15 years old 6 3.4 (1.6–7.5) 8 3.7 (1.9–7.3) 5 3.4 (1.4–7.9) 1 1.2 (0.2–7.8)
> 15 years old 405 18.8 (17.3–20.6) 521 26.1 (24.2–28.1) 489 22.6 (20.9–24.4) 504 23.0 (21.3–24.8)
All ages 411 17.7 (16.2–19.3) 529 23.9 (22.2–25.7) 494 21.4 (19.8–23.1) 505 22.1 (20.5–23.9)
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Fig. 2 Proportion of individuals based on score of age-adjusted antibody responses to multiple a P. vivax and b P. falciparum antigens by survey
time. Blue represents proportion of individuals with low age-adjusted antibody responses (score 1), yellow represents average (score 2), orange
represents higher than average (score 3) and red represents proportion of individuals with highest age-adjusted antibody responses (score 4)
Fig. 3 Age-seroprevalence plots for P. falciparum (a) and for P. vivax (b). Solid lines represent the fitted probability for being seropositive to either
of the two or five antigens for P. falciparum and P. vivax, respectively. Dashed lines represent the 95% confidence interval of these fits and red
triangles represent the observed proportion of seropositive per age decile. SCR value represents the average annual rate at which the population
become seropositive to any of the P. falciparum or P. vivax antigen, respectively
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the majority of fever cases were seen in quarter 2 when
the outbreak occurred (Additional file 2: Figure S2).
Discussion
The study found that analysing serological and spatial epi-
demiological data collected via health facilities in quarterly
cross-sectional surveys was a useful supplement to passive
data collection and could potentially be used to identify and
target areas that remain receptive to malaria, and therefore
at risk of outbreaks (Additional file 3, 4, 5, and 6). Consist-
ent with the parasitological data, the population-level SCR
estimates suggest very low level of transmission in the ≤ 15-
year-old population (current transmission). The SCRs
equate to 5 per 1000 and 20 per 1000 people seroconvert-
ing per year for P. falciparum and P. vivax, respectively. For
comparison, the SCRs in adults over 15 years old (historical
transmission) were 32 per 1000 and 66 per 1000 people for
P. falciparum and P. vivax, respectively. Moreover, spatial
analysis of age-adjusted antibody responses identified clus-
ters of high antibody responders in areas which subse-
quently report P. vivax cases. These findings support the
potential utility of serological tools to improve malaria sur-
veillance in the absence of active cases, and their incorpor-
ation in malaria elimination programmes. Multivariable
analysis suggests that surveillance could potentially priori-
tise targeting males and forest goers as they were the high-
risk populations who might reintroduce infections to a
community in the future.
Although the accuracy of the mapping exercise varied
within the eight health facilities (353–817m), the
addition of a relatively simple tablet-based participatory
mapping approach with a short questionnaire adminis-
tered during facility attendees’ interviews allowed the
collection of fine-scale spatial variation of malaria infec-
tions and exposure. If employed, this approach could it-
eratively improve spatial accuracy of public health
mapping at the local level [30]. Integrating spatial data
with age-adjusted antibody responses to a panel of mal-
aria antigens identified health facility catchment areas
with significantly higher antibody responses than the
population average. These clusters of high antibody re-
sponses were detected in the same areas across all four
surveys for both species and were the location for a mal-
aria outbreak during the study period. Importantly, the
serological outcomes highlighted the area prior to the
outbreak and, had this area been subject to targeting
with interventions or more in-depth surveillance, the
outbreak may have been prevented. Areas that were
most recently receptive to transmission could be tar-
geted with interventions as these are places that may be
most susceptible to outbreaks and this strategy is likely
to be more efficient than untargeted approaches to re-
duce transmission in low transmission settings [5]. Two
other clusters in Girimulyo 2 and Samigaluh 2 were
identified, suggesting that other high-risk areas are lo-
cated in the most forested areas of the region which also
Fig. 4 P. vivax age-seroprevalence plots and total number of P. vivax microscopy infections per health facility. Solid lines represent the fitted
probability for being seropositive to either of the five P. vivax antigens. Dashed lines represent the 95% confidence interval of these fits and red
triangles represent the observed proportion of seropositive per age decile. SCR value represents the average annual rate at which the population
become seropositive to any of the P. vivax antigen
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bordered with another malaria higher endemic setting
with ongoing transmission [61].
Whilst the microscopy data collected during the re-
peated surveys identified very few infections, and therefore
could not be utilised to identify risk factors, the numbers
of serological positives enabled the examination of risk
factors for exposure to infection within the population.
Our analysis found that people who were P. vivax sero-
positive were threefold more likely to be P. falciparum
seropositive. As there was no cross-reactivity evident from
the serological data, this suggests that the population have
been exposed to infections with both species, although
this exposure could have been historical. This implies that
both species are transmitted in similar areas and that these
places are, or were, particularly receptive to the transmis-
sion of malaria. Risk factor analysis for P. vivax seroposi-
tivity confirmed that people aged over 15 years old, males
and forest-related activities were associated with higher
exposure to malaria. These findings are consistent with
findings from previous studies in the area suggesting that
malaria infection is expected to be less common among
children compared to adults most likely due to a different
level of behavioural risk (night outdoor activities and
forest-related jobs such as loggers, coconut/palm tapper,
fruit farmer, etc.) which leads to higher exposure among
males and adults [7, 10, 31, 35]. Interestingly, higher
Table 3 Factors associated with P. vivax transmission in Kulon Progo District, Indonesia, 2018
Variable Total P. vivax seropositive Bivariate Multivariable
n (%) n % (95% CI) ORa (95% CI) p aORb (95% CI) p
Age (years)
≤ 15 623 (6.8) 80 12.9 (10.5–15.7) 1 1
16–30 2108 (23.1) 750 35.6 (33.6–37.6) 4.6 (3.6–5.9) 0.000 5.1 (3.9–6.6) 0.000
31–45 2531 (27.7) 1115 44.1 (42.1–46.0) 6.5 (5.0–8.3) 0.000 6.6 (5.1–8.7) 0.000
> 45 3880 (42.4) 1836 47.3 (45.8–48.9) 7.5 (5.9–9.7) 0.000 7.7 (5.9–10.0) 0.000
Gender
Female 5945 (65.0) 2309 38.8 (37.6–40.1) 1 1
Male 3206 (35.0) 1476 46.0 (44.3–47.8) 1.3 (1.2–1.4) 0.000 1.3 (1.2–1.5) 0.000
Status
Accompanying 1960 (21.4) 895 45.7 (43.5–47.9) 1
Patients 7191 (78.6) 2889 40.2 (39.0–41.3) 0.9 (0.8–1.0) 0.028
Occupation
Non-forest goers 2653 (29.0) 1023 38.6 (36.7–40.4) 1 1
Forest goers 2685 (29.4) 1393 51.9 (50.0–53.8) 1.6 (1.4–1.8) 0.000 1.2 (1.0–1.3) 0.012
Unemployed 3810 (41.6) 1368 35.9 (34.4–37.4) 0.9 (0.8–1.0) 0.011 1.0 (0.9–1.1) 0.446
Survey time
Quarter 1 2324 (25.4) 903 38.9 (36.9–40.9) 1 1
Quarter 2 2217 (24.2) 1024 46.2 (44.1–48.3) 1.4 (1.2–1.5) 0.000 1.5 (1.3–1.6) 0.000
Quarter 3 2328 (25.4) 930 40.0 (38.0–42.0) 1.1 (0.9–1.2) 0.348 1.0 (0.9–1.2) 0.524
Quarter 4 2283 (24.9) 928 40.7 (38.6–42.7) 1.1 (1.0–1.2) 0.196 1.0 (0.9–1.2) 0.799
Bed net use
No 6650 (72.7) 2556 38.4 (37.3–39.6) 1 1
Yes 2502 (27.3) 1229 49.1 (47.2–51.1) 1.2 (1.1–1.3) 0.000 1.2 (1.1–1.3) 0.001
Fever
No 8640 (94.9) 3604 41.7 (40.7–42.8) 1
Yes 465 (5.1) 164 35.3 (31.1–39.7) 0.6 (0.5–0.8) 0.000
Recent travel
No 7681 (84.1) 3171 41.3 (39.3–44.4) 1
Yes 1457 (15.9) 609 41.8 (40.2–42.4) 0.9 (0.8–1.1) 0.243
aBivariate OR adjusted by correlation at a health facility level
bMultivariable OR adjusted by other covariates with bivariate p value < 0.05, and correlation at a health facility level
Quarter 1: May–July 2017, Quarter 2: August–October 2017, Quarter 3: November 2017–January 2018, Quarter 4: February–April 2018
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Fig. 5 Spatial distribution of age-adjusted antibody responses to multiple P. vivax antigens over time of surveys overlaid with P. vivax microscopy
infections captured by the current surveillance systems. Black triangles represent P. vivax microscopy-positive households. Black circle indicates a
cluster of significantly higher than expected antibody responses detected using SaTScan (p value < 0.05)
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exposure was also associated with bed net use. The cover-
age and usage of bed nets was relatively low in this study
setting and may be indicative of people living in higher-
risk areas being more likely to use a net, potentially due to
the presence of more mosquitoes. The data suggest that
people ≤ 15 years old were more likely to be sleeping
under a bed net compared to adults over 15 years old.
This finding may also suggest that a bed net is no longer
effective to prevent transmission in the studied popula-
tion. Therefore, an alternative intervention such as tar-
geted repellent distribution for adults or impregnated
hammocks for forest workers could be useful to reduce
transmission in the future.
P. vivax seroprevalence was highest during the period of
August to October. This overlaps with the expected high
transmission season (August to December) and was also
the period when people in the study were most likely to re-
port recent travel. However, our analysis suggested that the
clusters of high exposure identified in this study were not
necessarily the place where recent travel from was reported.
A possible explanation of these findings is that the trans-
mission occurred after Ramadhan where people were more
likely to return to their region after several days or weeks of
travelling to areas of higher endemicity to gather and cele-
brate Eid day with their family. Previous studies indicated
migration and high rates of imported cases from higher
transmission areas as factors that linked to malaria resur-
gence and outbreaks in low transmission settings [10, 13,
31, 62]. A study in Zanzibar estimated that residents travel-
ling to other endemic settings contribute 1 to 15 times
more imported cases than visitors, highlight the importance
of strengthening surveillance to capture infection in travel-
lers in countries nearing elimination [63]. However, the
investigation conducted by the surveillance program did
not identify if there was a link between migration during or
after Ramadhan with the outbreak occurred in the period.
These findings suggest that surveillance needs to be intensi-
fied in periods with high population movement such as
during and/or after Ramadhan and during fruit (i.e. durian)
harvesting time which often coincides with the wet season
in the region, to enable early detection and responses to
prevent transmission in the future, particularly in receptive
areas identified in the study.
Our findings suggest that serological analysis can be used
to estimate heterogeneity of P. falciparum and P. vivax
transmission and predict high-risk areas from a single
health facility-based cross-sectional survey. This sampling
approach could be a more efficient surveillance strategy as
the serological sampling is performed (in addition to para-
sitological diagnosis) in well-established health infrastruc-
tures therefore allowing rapid treatment and surveillance
response if clinical cases are detected. On the other side,
the repeated surveys might potentially be more useful in
informing short-term changes in malaria exposure in other
endemic settings where malaria transmission is still on-
going and more intense.
Although the health facility surveys provide sufficient
samples to estimate burden of infection and transmission
level in the population, there were several limitations to
be considered when implementing the methods. Firstly,
we found that the facility survey approaches captured only
a small proportion of children under 15 years of age com-
pared to the general population. Whilst we have observed
risk is significantly higher in adults and the underrepre-
sentation of children may not be an issue for malaria in
this setting, it could limit the approach for general disease
surveillance. Routine data collected by the district health
office surveillance suggest that this could be due to the
low proportion of children attending public health facil-
ities in some areas where private health facilities may be
easier to access. This phenomenon might not be the case
in many other countries where often young children are
the most common demographic to attend health facilities.
Future studies in Indonesia could consider attendees to
private health facilities as an easy access group to improve
the facility-based sampling approach. In addition, surveys
based in facilities are likely to miss asymptomatic infec-
tions, as well as those occurring in people who choose not
to use public facilities. This is indicated by our finding
suggesting that majority of cases (61%) were captured by
the active case surveillance. Secondly, people living further
from facilities may be less likely to attend health facilities
resulting in the methods being less likely to detect clusters
of high exposure further from facilities. However, it is con-
ceivable that iterative refinements of the maps over time
with clinical and demographic data would improve this.
Inclusion of a mapping exercise in active surveillance per-
formed by community health workers would be useful to
capture heterogeneity in areas further from the facilities
or those not seeking care. It may also help to identify if
there are any spatial aspects to specific movement and be-
haviours. Recent travel was not significantly associated
with increased seropositivity, but being male and working
in the forest were and, whilst there was some evidence of
spatial autocorrelation in the data, this was not accounted
for in the regression modelling meaning estimates are
likely to be over-precise. There are potential benefits to
understanding the spatial context for risk behaviours
which may be influenced by season for farming or harvest-
ing and for traditional and religious holidays. The fourth
limitation is in the analysis and interpretation of the sero-
logical data. Whilst outwardly, the multiplex assay for
serological screening is attractive in increasing the number
of antigenic targets to both reduce the likelihood of miss-
ing individuals non-responsive to specific antigens and
simultaneously screen for multiple species, the best analyt-
ical approaches in combining data are still relatively un-
developed and validated. Using standard approaches based
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on seroprevalence, SCR and regression analysis has gener-
ated important observations but in future it will be im-
portant to combine these into more readily usable metrics
and/or platforms such as serological lateral flow devices
that offers more rapid test [64].
Conclusion
The health facility-based serological surveillance imple-
mented and evaluated in this study provides an alternative
approach for quickly obtaining parasitological, serological,
geolocation and risk factor data. A single survey is efficient
in supplementing the existing surveillance in very low en-
demic areas approaching zero cases, although the repeated
surveys might be more useful in informing short-term
changes in exposure in other higher endemic settings.
Combining these methods with novel multiplex serological
techniques could improve malaria surveillance capacity
and result in a better understanding of transmission dy-
namics, in the absence of infection detected by standard
diagnostic tools such as microscopy. Future work could ex-
pand the use of multiplex bead-based assays to include a
panel of other species of plasmodium antigens as well as to
other available neglected tropical diseases (NTDs) antigens
such as soil-transmitted helminths and filariasis to similarly
improve surveillance of these infections. How this ap-
proach is incorporated as a practical tool into programmes
will require significant technological and operational re-
finement [65] and financial assessment of the potential
benefit. However, the argument for serological surveillance
is particularly strong for P. vivax as there are no current
diagnostics to detect latent hypnozoites and this is what
the approach described in the manuscript has detected. Fi-
nally, reliability of implementing these methods would
need to be evaluated in other areas aimed at eliminating
malaria. Future works will need to assess the bottleneck of
implementing these methods to allow further integration
into existing surveillance systems.
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